drugset
drugset / Trial / NCT06015568

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

NCT06015568 ↗

Phase 1 Not yet recruiting 172 enrolled Betta Pharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerance of MCLA-129 combined with Befotertinib in patients with advanced non-small cell lung cancer with EGFR-sensitive mutations.

Timeline

Start
2023-09-01
Primary completion
2028-11-04
Completion
2029-07-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Befotertinib Small molecule 75 mg Oral
Subject Befotertinib Small molecule 100 mg Oral
Subject PAMVATAMIG Monoclonal antibody 1500 mg Intravenous
Subject PAMVATAMIG Monoclonal antibody 2000 mg Intravenous

Indications

non-small cell lung carcinoma